AssetMark Inc’s Dr. Reddy's Laboratories RDY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $429K | Buy |
29,640
+8,495
| +40% | +$115K | ﹤0.01% | 1272 |
|
|
2026
Q1 | $293K | Buy |
21,145
+2,240
| +12% | +$31.2K | ﹤0.01% | 1258 |
|
|
2025
Q4 | $265K | Sell |
18,905
-932
| -5% | -$13.1K | ﹤0.01% | 1238 |
|
|
2025
Q3 | $277K | Buy |
19,837
+988
| +5% | +$14.2K | ﹤0.01% | 1197 |
|
|
2025
Q2 | $283K | Sell |
18,849
-182,748
| -91% | -$2.61M | ﹤0.01% | 1142 |
|
|
2025
Q1 | $2.66M | Sell |
201,597
-3,118
| -2% | -$43K | 0.01% | 653 |
|
|
2024
Q4 | $3.23M | Buy |
204,715
+16,385
| +9% | +$246K | 0.01% | 601 |
|
|
2024
Q3 | $2.99M | Buy |
188,330
+14,180
| +8% | +$228K | 0.01% | 566 |
|
|
2024
Q2 | $2.65M | Sell |
174,150
-72,700
| -29% | -$1.04M | 0.01% | 546 |
|
|
2024
Q1 | $3.62M | Buy |
246,850
+8,295
| +3% | +$121K | 0.01% | 476 |
|
|
2023
Q4 | $3.32M | Buy |
238,555
+7,395
| +3% | +$98.9K | 0.01% | 458 |
|
|
2023
Q3 | $3.09M | Buy |
231,160
+225,480
| +3,970% | +$3.05M | 0.01% | 432 |
|
|
2023
Q2 | $71.7K | Sell |
5,680
-11,295
| -67% | -$132K | ﹤0.01% | 1005 |
|
|
2023
Q1 | $193K | Buy |
16,975
+13,320
| +364% | +$144K | ﹤0.01% | 834 |
|
|
2022
Q4 | $37.8K | Sell |
3,655
-380
| -9% | -$4.1K | ﹤0.01% | 1101 |
|
|
2022
Q3 | $42K | Buy |
4,035
+290
| +8% | +$3.09K | ﹤0.01% | 983 |
|
|
2022
Q2 | $41K | Sell |
3,745
-870
| -19% | -$9.46K | ﹤0.01% | 972 |
|
|
2022
Q1 | $51K | Buy |
4,615
+1,370
| +42% | +$15.5K | ﹤0.01% | 915 |
|
|
2021
Q4 | $42K | Buy |
3,245
+2,315
| +249% | +$29.2K | ﹤0.01% | 946 |
|
|
2021
Q3 | $12K | Sell |
930
-99,145
| -99% | -$1.32M | ﹤0.01% | 1023 |
|
|
2021
Q2 | $1.47M | Buy |
100,075
+12,430
| +14% | +$174K | 0.01% | 349 |
|
|
2021
Q1 | $1.08M | Buy |
87,645
+15,530
| +22% | +$199K | 0.01% | 359 |
|
|
2020
Q4 | $1.03M | Buy |
72,115
+30,850
| +75% | +$415K | 0.01% | 348 |
|
|
2020
Q3 | $574K | Buy |
41,265
+25,525
| +162% | +$304K | ﹤0.01% | 388 |
|
|
2020
Q2 | $167K | Buy |
15,740
+4,730
| +43% | +$48.1K | ﹤0.01% | 518 |
|
|
2020
Q1 | $89K | Buy |
11,010
+3,515
| +47% | +$29.3K | ﹤0.01% | 588 |
|
|
2019
Q4 | $61K | Buy |
7,495
+6,930
| +1,227% | +$54.7K | ﹤0.01% | 705 |
|
|
2019
Q3 | $4K | Buy |
+565
| New | +$4.2K | ﹤0.01% | 1080 |
|
|
2017
Q1 | – | Sell |
-20
| Closed | – | – | 1402 |
|
|
2016
Q4 | $0 | Buy |
+20
| New | +$186 | ﹤0.01% | 1358 |
|
|
2016
Q1 | – | Sell |
-115
| Closed | -$1K | – | 1365 |
|
|
2015
Q4 | $1K | Buy |
+115
| New | +$1.26K | ﹤0.01% | 1253 |
|
Other funds holding RDY
AIM
AssetMark Inc's RDY Position: Q2 2026 in Review
AssetMark Inc increased its Dr. Reddy's Laboratories (RDY) stake by 40% in Q2 2026, buying an estimated $115K and bringing the position to 29,640 shares worth $429K. The position accounts for ﹤0.01% of the portfolio, ranked #1272.
AssetMark Inc first reported a position in RDY in Q4 2015 and has held it in 30 quarters since. The position peaked at $3.62M in Q1 2024. 238 funds tracked by Wall St. Rank hold RDY as of Q2 2026.
- AssetMark Inc held 29,640 shares of Dr. Reddy's Laboratories worth $429K as of Q2 2026.
- AssetMark Inc bought 8,495 Dr. Reddy's Laboratories shares in Q2 2026, an estimated $115K.
- Dr. Reddy's Laboratories made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #1272 holding.
- AssetMark Inc first reported a position in Dr. Reddy's Laboratories in Q4 2015 and has held it in 30 quarters since.
- AssetMark Inc's Dr. Reddy's Laboratories position peaked at $3.62M in Q1 2024.
- 238 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q2 2026.
Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.